REG - N4 Pharma PLC - SRI Research Update

N4 PharmaAnnouncement

17/09/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240917:nRSQ4828Ea&default-theme=true

RNS Number : 4828E  N4 Pharma PLC  17 September 2024

17 September 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

SRI Research Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to provide a further update on its work with SRI
International ("SRI").

 

Further to the Company's announcement on 20 August 2024, the Company has now
successfully demonstrated that the selected cargo, when combined with Nuvec®
and SRI's Fox Three Molecular Guidance System ("MGS"), is performing as
expected  and has therefore completed the first stage of its collaboration
project with SRI.  More information will be released soon.

 

Find more information and an additional video by Nigel Theobald, CEO and
submit any questions via the N4 Pharma investor hub:
https://investors.n4pharma.com/link/MrDmnP
(https://investors.n4pharma.com/link/MrDmnP) .

 

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We have now shown that not only is Nuvec® capable of modification with a
ligand to target specific cells, but also that the combined new Nuvec®
nanoparticle retains its ability to knockdown the target gene.

 

"We will add this information to our combined marketing pitch deck and both
SRI and N4 Pharma will present this data and its implications to major pharma
and biotech players that need a targeting delivery system for their nucleic
acid programs."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub            Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKOBKOBKKDCD